When: Q3 earnings beat with Cobenfy >$200M/quarter

Then: Re-engage on fundamental acceleration

Exit minimum 50% of position; exit residual if 200 SMA fails; reject 50 SMA re-entry; re-enter only on confirmed stable base reclaiming 10 EMA at $60.53 with MACD turn, or on fresh Eliquis de-risking catalyst.

• Conservative position asks not 'how much to trim' but 'what minimum position is required by fiduciary duty,' arguing minimum should be zero absent specific income mandate
• 4.22% dividend yield does not justify residual exposure because 2+ years of compounding required to recoup capital destruction, while patent cliff threatens the FCF supporting that dividend
• Re-entry trigger at 50 SMA ($63.64) requires 6.8% recovery from current close (59.58) with no evidence this level is reachable given bearish alignment across all moving averages, negative MACD, and RSI at 37 with no capitulation signal
• Stop placement at 200 SMA ($58.27) is reactive rather than proactive risk management; conservative approach is to size down before reaching critical support, not maintain position dependent on it holding
• Beta of 0.18 indicates lack of market correlation, not absence of company-specific risk; low beta creates false comfort while Eliquis cliff, 2.02 D/E ratio, $17B intangible erosion, and Karuna write-down precedent pose independent threats
• Higher-for-longer rate environment with 96% no-cut pricing keeps refinancing costs elevated on $47B total debt, making 5.18B net debt repayment in 2025 glacial against 34.9B base at current rates
• Zero catalysts, zero social chatter, zero institutional defense means stock trades on flows and positioning alone with path of least resistance lower
• Insufficient evidence to support 200 SMA holding; once that level fails, next reference points are much lower

→ vs aggressive: Residual exposure retained 'only if income mandate requires it' — conservative analyst demands specific identification of that mandate; no binding contractual obligation to hold BMY for income found in fundamentals or technical reports

→ vs aggressive: Re-entry at 50 SMA ($63.64) presupposes recovery that has zero data support in a stock with bearish alignment, negative MACD, RSI at 37, no capitulation signal, hostile macro backdrop, and smart-money exit at 36.85M shares

→ vs aggressive: Stop at 200 SMA ($58.27) is one bad session from triggering with only $1.31 cushion against $1.40 ATR, making it reactive rather than proactive risk management for a fundamentally deteriorating name

→ vs aggressive: Low beta (0.18) does not make BMY defensive against idiosyncratic risks: Eliquis cliff, 2.02 D/E, $17B intangible erosion, Karuna write-down, and refinancing risk in higher-for-longer environment are company-specific and unaffected by market correlation

→ vs aggressive: Trim recommendation of 30 to 50% is directionally correct but still leaves firm with asymmetric downside exposure; conservative position is to push toward higher end (50% minimum) with pre-committed exit plan

Trim 40 percent, stop at 57.50, re-enter only on momentum confirmation above 10 EMA with positive MACD histogram, collect dividend on residual

• Current price at 59.58; 50 SMA re-entry trigger at 63.64 is 6.8 percent above and unsupported by data
• BMY FCF of 12.85 billion against 121.7 billion market cap represents approximately 10.5 percent FCF yield; dividend consumes 36 percent of FCF
• Net debt repaid in 2025 of 5.18 billion is meaningful relative to 14.3 billion in 2024 charges being cleaned up
• FCF yield and cash generation represent the asset's actual moat in a no-cut macro environment
• Credit is stressed, not broken—stressed has option value, zero has none
• Stop at 58.27 is too tight relative to 1.40 ATR and technical significance of 200 SMA; 57.50 is below 200 SMA and allows 2-3 days of volatility room
• Pre-committed exit on 200 SMA break with above-average volume forces exit into worst tape on structural breakdown scenario
• Beta of 0.18 provides genuine diversification value in portfolios holding cyclicals or growth names
• Re-entry should be on momentum confirmation (10 EMA at 60.53, above-average volume, MACD histogram turning positive), not price aspiration at 50 SMA
• Macro backdrop: 96 percent no-cut, 6 percent recession; fundamental picture stressed but cash-generative; reassess when earnings, Eliquis policy news, or FRED data arrives

→ vs aggressive: Re-entry trigger at 50 SMA (63.64) is unsupported by data—requires 6.8 percent upside in a stock with bearish MA alignment, negative MACD, RSI at 37, no capitulation signal, and no positive catalyst; that is hope dressed as discipline, not data-driven re-entry

→ vs aggressive: Underweighted the cash generation story—10.5 percent FCF yield against 5.18 billion in net debt repaid is not 'glacial' given the 14.3 billion in 2024 charges being cleaned up; the ice cube is generating real cash while it melts

→ vs conservative: Circular reasoning on income mandate—absence of mandate in the data is a data gap, not confirmation that no mandate exists; inferring absence from silence is the same error the aggressive analyst made

→ vs conservative: Pre-committed exit on 200 SMA break with above-average volume creates the worst outcome being avoided—forced exit at worst level on structural breakdown, which is pre-committed reactivity not proactivity

→ vs conservative: Overcorrecting on beta—low beta of 0.18 provides real diversification value; a 30-50 percent trim leaves a residual small enough that idiosyncratic risk is bounded while still providing diversification and yield benefits